Skip to content

Assessment of a functional tea assisted in reducing uric acid and preventing gout in human feeding trials

Assessment of a functional tea assisted in reducing uric acid and preventing gout in human feeding trials

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020054
Enrollment
Unknown
Registered
2018-12-12
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary gout

Interventions

Group I:Oral test sample I continuously for 90 days
Group II:Oral test sample II continuously for 90 days

Sponsors

Guangzhou Hongyun Medical Scientific and Technological Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-60 years old; 2. Serum uric acid value: male > 420 micromol/L; female > 360 micromol/L; 3. Has a history of gout attacks, and conforms to the diagnostic criteria for acute gouty arthritis established by the American Rheumatological Society (ACR) in 2012; 4. The course of gout was more than 1 year, and the number of acute attacks was more than 2 times in the past 1 year; 5. Subject's consent and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who do not meet the above inclusion criteria; 2. Secondary hyperuricemia; 3. The drugs affecting blood uric acid could not be stopped; 4. Late gouty arthritis with severe kidney stones and joint deformations; 5. For the past two weeks, the patients treated with allopurinol and benzbromarone were treated with hypouric acid/antigout drugs; 6. Hormone drugs were used within 6 months; 7. Overlapping other rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome and severe knee osteoarthritis; 8. Patients with serious diseases such as heart, brain, liver, kidney and hematopoietic system; 9. Pregnant or lactating women, psychiatric patients, etc.; 10. Those with severe bone destruction and severe impairment of limb function; 11. pairs of drug allergic patients; 12. Those who have participated in similar clinical trials in 121 years.

Design outcomes

Primary

MeasureTime frame
serum uric acid;

Secondary

MeasureTime frame
ESR;CRP;TCHO;TG;HDL-C;LDL-G;GLU;Scoring of local symptoms and signs of joints;Quantitative evaluation of TCM symptom classification;

Countries

China

Contacts

Public ContactYAN QUN CHAO

Guangzhou Hongyun Medical Scientific and Technological Co.,Ltd.

yqunchao@163.com+86 13902283853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026